AHCY and diabetic cardiomyopathy: Notably, inhibiting SAHH weakened the beneficial effects of normal BMSCs on diabetic cardiomyopathy, while enhancing the expression of SAHH in diabetic BMSCs improved heart function, potentially by activating the Nrf2-mediated antioxidant signal (170).